myo-inositol/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases gestational diabetes mellitus incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Incidence of GDM was significantly reduced in the myo-inositol group compared with the placebo group: 6 vs. 15.3%, respectively (P = 0.04).”
Quoted verbatim from myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study.. - Study
- RCT
- Dose
- 2 g myo-inositol plus 200 µg folic acid twice a day
- Population
- pregnant outpatients with a parent with type 2 diabetes, treated from the end of the first trimester; folic acid 200 µg twice daily given in both arms
myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study.2013PMID:23340885Permalink
Keep reading
- Everything the graph holds on myo-inositol
- Every compound studied against Gestational diabetes mellitus incidence
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PBR769GSXNSGSP8AP8DB2Y